AbL Diagnostics SA (ABLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has a cash flow conversion efficiency ratio of 0.069x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€479.46K ≈ $560.54K USD) by net assets (€6.93 Million ≈ $8.10 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AbL Diagnostics SA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
AbL Diagnostics SA - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how AbL Diagnostics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AbL Diagnostics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbL Diagnostics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TWL Holdings Bhd
KLSE:7079
|
-0.043x |
|
Cengild Medical Berhad
KLSE:0243
|
0.008x |
|
Digital Currency X Technology Inc.
NASDAQ:DCX
|
-0.005x |
|
Harrisons Malayalam Limited
NSE:HARRMALAYA
|
0.033x |
|
Routon Electronic Co Ltd
SHG:600355
|
0.032x |
|
Duck Yang Ind
KO:024900
|
0.240x |
|
JC Chemical Co. Ltd
KQ:137950
|
0.048x |
|
3I Infrastructure PLC
LSE:3IN
|
-0.006x |
Annual Cash Flow Conversion Efficiency for AbL Diagnostics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of AbL Diagnostics SA from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is AbL Diagnostics SA worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €7.63 Million ≈ $8.92 Million |
€1.51 Million ≈ $1.76 Million |
0.198x | +209.34% |
| 2024-12-31 | €7.49 Million ≈ $8.75 Million |
€-1.35 Million ≈ $-1.58 Million |
-0.181x | -231.96% |
| 2023-12-31 | €6.77 Million ≈ $7.91 Million |
€926.43K ≈ $1.08 Million |
0.137x | +1804.30% |
| 2022-12-31 | €6.75 Million ≈ $7.90 Million |
€-54.25K ≈ $-63.42K |
-0.008x | +62.89% |
| 2021-12-31 | €2.62 Million ≈ $3.06 Million |
€-56.69K ≈ $-66.28K |
-0.022x | -273.21% |
| 2020-12-31 | €2.36 Million ≈ $2.76 Million |
€29.51K ≈ $34.50K |
0.012x | +131.83% |
| 2019-12-31 | €7.09 Million ≈ $8.29 Million |
€-278.40K ≈ $-325.48K |
-0.039x | -446.32% |
| 2018-12-31 | €7.15 Million ≈ $8.36 Million |
€81.10K ≈ $94.82K |
0.011x | -87.62% |
| 2017-12-31 | €7.37 Million ≈ $8.62 Million |
€675.20K ≈ $789.38K |
0.092x | -- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more